InvestSMART

Argenica Therapeutics Limited (ASX:AGN)

ALERT: Price-sensitive ASX Announcement for AGN
Current share price for AGN : $0.175 -0.015 (-7.89%)+
Announcement
Release
26 Aug 2026 4:29PM
Price at Release
$0.190
Full Release
download
Summary
The Appendix 4E and Annual Report of Argenica Therapeutics Limited for the financial year ending 30 June 2026 outlines the company's financial performance and position. The report highlights a significant loss after income tax of $1,365,362, an improvement from the previous year's loss of $7,170,347. Revenue for the year increased to $5,696,563 compared to $3,726,499 in 2025. Cash and cash equivalents decreased to $6,362,541 from $10,555,160 in the previous year, reflecting the company's cash use in operations and financing activities. The report details the changes in equity, including an increase in issued capital to $29,816,439, and a reduction in reserves and accumulated losses. The report also covers remuneration details for directors and key management personnel, emphasizing a performance-based compensation framework. The company did not engage external remuneration consultants in the financial year and received significant support at the Annual General Meeting for its remuneration report. There were no dividends declared for the financial year.
Key Points
  • Loss after income tax was $1,365,362, an improvement from the previous year's loss.
  • Revenue increased to $5,696,563.
  • Cash and cash equivalents decreased to $6,362,541.
  • Issued capital increased to $29,816,439.
  • No external remuneration consultants were engaged.
  • High support for remuneration report at the AGM.
  • No dividends declared for the year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.